<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550224</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-22794</org_study_id>
    <secondary_id>HEMAML0017</secondary_id>
    <nct_id>NCT01550224</nct_id>
  </id_info>
  <brief_title>Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase 2 Study of Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to first determine if temozolomide plus vorinostat in combination
      can control relapsed or refractory acute myeloid leukemia (AML) and determine if this
      combination can be safely taken. The study will look at the side effects of the Temozolomide
      plus Vorinostat in combination and whether the treatment schedule is tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the study is to determine the clinical efficacy as determined by the
      rate of morphological complete remission, of 2 different treatment regimens of temozolomide
      and vorinostat administered to 2 distinct groups of participants patients with AML and poor
      prognostic features. Participants will be allocated to treatment on the basis of
      O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2013</start_date>
  <completion_date type="Actual">November 17, 2014</completion_date>
  <primary_completion_date type="Actual">November 17, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>36 months</time_frame>
    <description>This study evaluates the clinical efficacy of temozolomide + vorinostat, as assessed by the rate of morphological complete remission (mCR) at 36 months. mCR is defined as the morphologic leukemia-free state (&lt; 5% blasts in bone marrow sample that has marrow spicules; ≥ 200 nucleated cells; no blasts with Auer rods; no persistence of extramedullary disease) plus absolute neutrophil count (ANC) &gt; 1,000/µL and platelets ≥ 100,000/µL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Acute Myeloid Leukemia With 11q23-abnormality in Relapse</condition>
  <arm_group>
    <arm_group_label>Group 1 - Methylated MGMT promoter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Non-Methylated MGMT promoter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>An alkylating agent administered:
Group 2: 100 mg/m²/day for 14 days Both groups: 200 mg/m²/day for 7days</description>
    <arm_group_label>Group 1 - Methylated MGMT promoter</arm_group_label>
    <arm_group_label>Group 2 - Non-Methylated MGMT promoter</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temcad</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>A synthetic hydroxamic acid derivative with antineoplastic activity administered at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.</description>
    <arm_group_label>Group 1 - Methylated MGMT promoter</arm_group_label>
    <arm_group_label>Group 2 - Non-Methylated MGMT promoter</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Carneiro de Medeiros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Bruno C. Medeiros</investigator_full_name>
    <investigator_title>Associate Professor of Medicine (Hematology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

